300 mg benfotiamine (provitamin B1)
  • Gluten free
  • Lactose free

milgamma® protekt : For the treatment of nerve damages due to vitamin B1 deficiency

Neuropathies (nerve damage) resulting from vitamin B1 deficiency and associated symptoms such as tingling, burning or numb feet can be easily and effectively remedied. Therefore, rely on a vitamin B1 therapy with milgamma® protekt.

  • Its active substance benfotiamine treats vitamin B1 deficiency as a cause of nerve damage
  • Effectively relieves tingling, burning and numbness in the feet
  • Benfotiamine is absorbed by the body five times better than conventional vitamin B1.1
  • Well tolerated
  • Non-prescription
  • Pharmacy exclusive

Application area: vitamin B1 deficiency as a cause of nerve damage

milgamma® protekt is suitable for the therapy or prophylaxis of clinical vitamin B1 deficiencies, provided these cannot be corrected nutritionally. milgamma® protekt is used for the treatment of neuropathies and cardiovascular disorders caused by vitamin B1 deficiency.

Dosage and use

The tablets are best to be taken by swallowing without chewing with sufficient fluid. The duration of administration is determined by the therapeutic response. For the treatment of neuropathies, milgamma® protekt tablets should be taken initially over a period of at least three weeks. Subsequently, further treatment with milgamma® protekt should be carried out according to the therapeutic success. If no efficacy or a too slight efficacy is recognizable after four weeks, the treatment of the complaints should be examined.

One tablet contains benfotiamine (lipid-soluble vitamin B1 derivative) 300 mg. For other ingredients, please refer to the direction for use.

milgamma® protekt. Active substance: Benfotiamine. Therapeutic indications: Treatment of neuropathies and cardiovascular disorders that are caused by vitamin B1 deficiency. IIf you have any questions about risks and side effects, please read the patient information leaflet and ask your doctor or pharmacist. Wörwag Pharma GmbH & Co. KG, 71034 Böblingen

30 film-coated tablets: PZN 01528157

60 film-coated tablets: PZN 17414438

90 film-coated tablets: PZN 01529731

milgamma® protect – your solution for nerve damage caused by diabetes-related vitamin B1 deficiency

People with diabetes often may become aware of their nerve damage through altered sensations like tingling, burning, numbness and pain in the feet. This nerve damage (neuropathies) is often caused by a vitamin B1 deficiency. What starts with slight sensations like tingling or burning, can lead to significant pain and numbness. When heat, cold, pressure and pain are no longer felt, problems can be expected. If foot injuries are not perceived, they often remain unrecognized and untreated. Various consequences could follow leading up to the ‘diabetic foot syndrome’.

milgamma® protekt can contribute to successfully counteracting these nerve disorders. It contains the active substance benfotiamine, a precursor of vitamin B1, that effectively compensates for the vitamin B1 deficiency which is common among diabetic patients. milgamma® protekt compensates the nerve damaging vitamin B1 deficiency and relieves the symptoms of tingling, burning and numbness in the feet with only one tablet per day.

Vitamin B1 deficiency in diabetics
Diabetics have an increased risk of vitamin B1 deficiency: they excrete more of the important "nerve vitamin" via the kidneys. This can easily lead to a vitamin B1 deficiency2, which can cause or exacerbate neuropathies. What starts with mild symptoms such as a tingling or burning sensation can lead to severe pain and numbness in the legs. If the sensation of heat, cold, pressure and pain is also lost, serious problems can be expected: Injuries to the foot are no longer perceived and are therefore often not recognized and treated.

1 Schreeb KH, Freudenthaler S, Vormfelder SV et al. Comparative bioavailability of two vitamin B1 preparations: benfotiamine and thiamine mononitrate. Eur J Clin Pharmacol 1997; 52 (4): 319–320.
2 Thornalley PJ, Babaei-Jadidi R, Al Ali H et al. High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia 2007 Oct; 50 (10): 2164–2170.

Wörwag Pharma stands for a healthier life

We specialize in the prevention and treatment of diabetic comorbidities and secondary diseases and support you in maintaining or restoring your health.
foundation in Germany
sites worldwide
This is us
We're here to help you!
Contact us